APO Research
Talk to an analyst

APO RESEARCH · REPORT

Central Nervous System (CNS) Drug

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Central Nervous System (CNS) Drug Market Analysis and Forecast 2026-2032

31 December 2025191 pages

Choose your research edition.

Industry ResearchCentral Nervous System (CNS) Drug Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal Central Nervous System (CNS) Drug Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Central Nervous System (CNS) Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Central Nervous System (CNS) Drug Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Central Nervous System (CNS) Drug Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Central Nervous System (CNS) Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Central Nervous System (CNS) Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Central Nervous System (CNS) Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Central Nervous System (CNS) Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Central Nervous System (CNS) Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Central Nervous System (CNS) Drug include Tekeda, Teva, Shanghai Fosun, Johnson & Johnson, Novartis AG, Roche, Eli Lilly, Jiangsu Nhwa Pharmaceutical Co., Ltd. and Pfizer Inc, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Central Nervous System (CNS) Drug, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Central Nervous System (CNS) Drug, also provides the revenue of main regions and countries. Of the upcoming market potential for Central Nervous System (CNS) Drug, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Central Nervous System (CNS) Drug revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Central Nervous System (CNS) Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Central Nervous System (CNS) Drug revenue, projected growth trends, production technology, application and end-user industry.

Central Nervous System (CNS) Drug Segment by Company

Tekeda

Teva

Shanghai Fosun

Johnson & Johnson

Novartis AG

Roche

Eli Lilly

Jiangsu Nhwa Pharmaceutical Co., Ltd.

Pfizer Inc

GSK

UCB

Otsuka Pharmaceutical Co., Ltd

Boehringer Ingelheim

Biogen Inc

Central Nervous System (CNS) Drug Segment by Type

Prescription Drugs

OTC

Central Nervous System (CNS) Drug Segment by Application

Epilepsy Drugs

MS Therapeutics

Antipsychotic Drugs

Depression Drugs

Others

Central Nervous System (CNS) Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Central Nervous System (CNS) Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Central Nervous System (CNS) Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Central Nervous System (CNS) Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Central Nervous System (CNS) Drug in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Central Nervous System (CNS) Drug company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Central Nervous System (CNS) Drug revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Central Nervous System (CNS) Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Prescription Drugs Major Player Table 3. OTC Major Player Table 4. Global Central Nervous System (CNS) Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Epilepsy Drugs Major Player Table 6. MS Therapeutics Major Player Table 7. Antipsychotic Drugs Major Player Table 8. Depression Drugs Major Player Table 9. Others Major Player Table 10. Central Nervous System (CNS) Drug Industry Trends Table 11. Central Nervous System (CNS) Drug Industry Drivers Table 12. Central Nervous System (CNS) Drug Industry Opportunities and Challenges Table 13. Central Nervous System (CNS) Drug Industry Restraints Table 14. Global Central Nervous System (CNS) Drug Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 15. Global Central Nervous System (CNS) Drug Market Size by Region (2021-2026) & (US$ Million) Table 16. Global Central Nervous System (CNS) Drug Market Share by Region (2021-2026) Table 17. Global Central Nervous System (CNS) Drug Market Size by Region (2027-2032) & (US$ Million) Table 18. Global Central Nervous System (CNS) Drug Market Share by Region (2027-2032) Table 19. Global Central Nervous System (CNS) Drug Revenue by Players (US$ Million) & (2021-2026) Table 20. Global Central Nervous System (CNS) Drug Revenue Market Share by Players (2021-2026) Table 21. Global Central Nervous System (CNS) Drug Key Players Ranking, 2024 VS 2025 VS 2026 Table 22. Global Central Nervous System (CNS) Drug Key Players Headquarters & Area Served Table 23. Global Central Nervous System (CNS) Drug Players, Product Type & Application Table 24. Global Central Nervous System (CNS) Drug Players Establishment Date Table 25. Global Players Market Concentration Ratio (CR5 and HHI) Table 26. Global Central Nervous System (CNS) Drug by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 27. Global Central Nervous System (CNS) Drug Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Central Nervous System (CNS) Drug Revenue by Type (2021-2026) & (US$ Million) Table 29. Global Central Nervous System (CNS) Drug Revenue by Type (2027-2032) & (US$ Million) Table 30. Global Central Nervous System (CNS) Drug Revenue Market Share by Type (2021-2026) Table 31. Global Central Nervous System (CNS) Drug Revenue Market Share by Type (2027-2032) Table 32. Global Central Nervous System (CNS) Drug Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Central Nervous System (CNS) Drug Revenue by Application (2021-2026) & (US$ Million) Table 34. Global Central Nervous System (CNS) Drug Revenue by Application (2027-2032) & (US$ Million) Table 35. Global Central Nervous System (CNS) Drug Revenue Market Share by Application (2021-2026) Table 36. Global Central Nervous System (CNS) Drug Revenue Market Share by Application (2027-2032) Table 37. Tekeda Company Information Table 38. Tekeda Business Overview Table 39. Tekeda Central Nervous System (CNS) Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 40. Tekeda Central Nervous System (CNS) Drug Product Portfolio Table 41. Tekeda Recent Development Table 42. Teva Company Information Table 43. Teva Business Overview Table 44. Teva Central Nervous System (CNS) Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 45. Teva Central Nervous System (CNS) Drug Product Portfolio Table 46. Teva Recent Development Table 47. Shanghai Fosun Company Information Table 48. Shanghai Fosun Business Overview Table 49. Shanghai Fosun Central Nervous System (CNS) Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 50. Shanghai Fosun Central Nervous System (CNS) Drug Product Portfolio Table 51. Shanghai Fosun Recent Development Table 52. Johnson & Johnson Company Information Table 53. Johnson & Johnson Business Overview Table 54. Johnson & Johnson Central Nervous System (CNS) Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 55. Johnson & Johnson Central Nervous System (CNS) Drug Product Portfolio Table 56. Johnson & Johnson Recent Development Table 57. Novartis AG Company Information Table 58. Novartis AG Business Overview Table 59. Novartis AG Central Nervous System (CNS) Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 60. Novartis AG Central Nervous System (CNS) Drug Product Portfolio Table 61. Novartis AG Recent Development Table 62. Roche Company Information Table 63. Roche Business Overview Table 64. Roche Central Nervous System (CNS) Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 65. Roche Central Nervous System (CNS) Drug Product Portfolio Table 66. Roche Recent Development Table 67. Eli Lilly Company Information Table 68. Eli Lilly Business Overview Table 69. Eli Lilly Central Nervous System (CNS) Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 70. Eli Lilly Central Nervous System (CNS) Drug Product Portfolio Table 71. Eli Lilly Recent Development Table 72. Jiangsu Nhwa Pharmaceutical Co., Ltd. Company Information Table 73. Jiangsu Nhwa Pharmaceutical Co., Ltd. Business Overview Table 74. Jiangsu Nhwa Pharmaceutical Co., Ltd. Central Nervous System (CNS) Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 75. Jiangsu Nhwa Pharmaceutical Co., Ltd. Central Nervous System (CNS) Drug Product Portfolio Table 76. Jiangsu Nhwa Pharmaceutical Co., Ltd. Recent Development Table 77. Pfizer Inc Company Information Table 78. Pfizer Inc Business Overview Table 79. Pfizer Inc Central Nervous System (CNS) Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 80. Pfizer Inc Central Nervous System (CNS) Drug Product Portfolio Table 81. Pfizer Inc Recent Development Table 82. GSK Company Information Table 83. GSK Business Overview Table 84. GSK Central Nervous System (CNS) Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 85. GSK Central Nervous System (CNS) Drug Product Portfolio Table 86. GSK Recent Development Table 87. UCB Company Information Table 88. UCB Business Overview Table 89. UCB Central Nervous System (CNS) Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 90. UCB Central Nervous System (CNS) Drug Product Portfolio Table 91. UCB Recent Development Table 92. Otsuka Pharmaceutical Co., Ltd Company Information Table 93. Otsuka Pharmaceutical Co., Ltd Business Overview Table 94. Otsuka Pharmaceutical Co., Ltd Central Nervous System (CNS) Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. Otsuka Pharmaceutical Co., Ltd Central Nervous System (CNS) Drug Product Portfolio Table 96. Otsuka Pharmaceutical Co., Ltd Recent Development Table 97. Boehringer Ingelheim Company Information Table 98. Boehringer Ingelheim Business Overview Table 99. Boehringer Ingelheim Central Nervous System (CNS) Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. Boehringer Ingelheim Central Nervous System (CNS) Drug Product Portfolio Table 101. Boehringer Ingelheim Recent Development Table 102. Biogen Inc Company Information Table 103. Biogen Inc Business Overview Table 104. Biogen Inc Central Nervous System (CNS) Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 105. Biogen Inc Central Nervous System (CNS) Drug Product Portfolio Table 106. Biogen Inc Recent Development Table 107. North America Central Nervous System (CNS) Drug Revenue by Type (2021-2026) & (US$ Million) Table 108. North America Central Nervous System (CNS) Drug Revenue by Type (2027-2032) & (US$ Million) Table 109. North America Central Nervous System (CNS) Drug Revenue by Application (2021-2026) & (US$ Million) Table 110. North America Central Nervous System (CNS) Drug Revenue by Application (2027-2032) & (US$ Million) Table 111. North America Central Nervous System (CNS) Drug Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 112. North America Central Nervous System (CNS) Drug Revenue by Country (2021-2026) & (US$ Million) Table 113. North America Central Nervous System (CNS) Drug Revenue by Country (US$ Million) & (2027-2032) Table 114. Europe Central Nervous System (CNS) Drug Revenue by Type (2021-2026) & (US$ Million) Table 115. Europe Central Nervous System (CNS) Drug Revenue by Type (2027-2032) & (US$ Million) Table 116. Europe Central Nervous System (CNS) Drug Revenue by Application (2021-2026) & (US$ Million) Table 117. Europe Central Nervous System (CNS) Drug Revenue by Application (2027-2032) & (US$ Million) Table 118. Europe Central Nervous System (CNS) Drug Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 119. Europe Central Nervous System (CNS) Drug Revenue by Country (2021-2026) & (US$ Million) Table 120. Europe Central Nervous System (CNS) Drug Revenue by Country (US$ Million) & (2027-2032) Table 121. China Central Nervous System (CNS) Drug Revenue by Type (2021-2026) & (US$ Million) Table 122. China Central Nervous System (CNS) Drug Revenue by Type (2027-2032) & (US$ Million) Table 123. China Central Nervous System (CNS) Drug Revenue by Application (2021-2026) & (US$ Million) Table 124. China Central Nervous System (CNS) Drug Revenue by Application (2027-2032) & (US$ Million) Table 125. Asia Central Nervous System (CNS) Drug Revenue by Type (2021-2026) & (US$ Million) Table 126. Asia Central Nervous System (CNS) Drug Revenue by Type (2027-2032) & (US$ Million) Table 127. Asia Central Nervous System (CNS) Drug Revenue by Application (2021-2026) & (US$ Million) Table 128. Asia Central Nervous System (CNS) Drug Revenue by Application (2027-2032) & (US$ Million) Table 129. Asia Central Nervous System (CNS) Drug Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 130. Asia Central Nervous System (CNS) Drug Revenue by Region (US$ Million) & (2021-2026) Table 131. Asia Central Nervous System (CNS) Drug Revenue by Region (US$ Million) & (2027-2032) Table 132. SAMEA Central Nervous System (CNS) Drug Revenue by Type (2021-2026) & (US$ Million) Table 133. SAMEA Central Nervous System (CNS) Drug Revenue by Type (2027-2032) & (US$ Million) Table 134. SAMEA Central Nervous System (CNS) Drug Revenue by Application (2021-2026) & (US$ Million) Table 135. SAMEA Central Nervous System (CNS) Drug Revenue by Application (2027-2032) & (US$ Million) Table 136. SAMEA Central Nervous System (CNS) Drug Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 137. SAMEA Central Nervous System (CNS) Drug Revenue by Country (2021-2026) & (US$ Million) Table 138. SAMEA Central Nervous System (CNS) Drug Revenue by Country (US$ Million) & (2027-2032) Table 139. Research Programs/Design for This Report Table 140. Authors List of This Report Table 141. Secondary Sources Table 142. Primary Sources List of Figures Figure 1. Central Nervous System (CNS) Drug Image Figure 2. Global Central Nervous System (CNS) Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Central Nervous System (CNS) Drug Market Size Share 2021 VS 2025 VS 2032 Figure 4. Prescription Drugs Image Figure 5. OTC Image Figure 6. Global Central Nervous System (CNS) Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Central Nervous System (CNS) Drug Market Size Share 2021 VS 2025 VS 2032 Figure 8. Epilepsy Drugs Image Figure 9. MS Therapeutics Image Figure 10. Antipsychotic Drugs Image Figure 11. Depression Drugs Image Figure 12. Others Image Figure 13. Global Central Nervous System (CNS) Drug Market Size (US$ Million) & (2021-2032) Figure 14. Global Central Nervous System (CNS) Drug Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global Central Nervous System (CNS) Drug Market Share by Region: 2021 VS 2025 VS 2032 Figure 16. Global Central Nervous System (CNS) Drug Players Revenue Share Top 10 and Top 5 in 2025 Figure 17. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global Central Nervous System (CNS) Drug Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Central Nervous System (CNS) Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 20. Global Central Nervous System (CNS) Drug Revenue Market Share by Type (2021-2032) Figure 21. Global Central Nervous System (CNS) Drug Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Central Nervous System (CNS) Drug Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 23. Global Central Nervous System (CNS) Drug Revenue Market Share by Application (2021-2032) Figure 24. North America Central Nervous System (CNS) Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 25. North America Central Nervous System (CNS) Drug Revenue Share by Type (2021-2032) Figure 26. North America Central Nervous System (CNS) Drug Revenue Share by Application (2021-2032) Figure 27. North America Central Nervous System (CNS) Drug Revenue Share by Country (2021-2032) Figure 28. United States Central Nervous System (CNS) Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Canada Central Nervous System (CNS) Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Mexico Central Nervous System (CNS) Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Europe Central Nervous System (CNS) Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 32. Europe Central Nervous System (CNS) Drug Revenue Share by Type (2021-2032) Figure 33. Europe Central Nervous System (CNS) Drug Revenue Share by Application (2021-2032) Figure 34. Europe Central Nervous System (CNS) Drug Revenue Share by Country (2021-2032) Figure 35. Germany Central Nervous System (CNS) Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. France Central Nervous System (CNS) Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. U.K. Central Nervous System (CNS) Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Italy Central Nervous System (CNS) Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Spain Central Nervous System (CNS) Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Russia Central Nervous System (CNS) Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Netherlands Central Nervous System (CNS) Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Nordic Countries Central Nervous System (CNS) Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. China Central Nervous System (CNS) Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 44. China Central Nervous System (CNS) Drug Revenue Share by Type (2021-2032) Figure 45. China Central Nervous System (CNS) Drug Revenue Share by Application (2021-2032) Figure 46. Asia Central Nervous System (CNS) Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 47. Asia Central Nervous System (CNS) Drug Revenue Share by Type (2021-2032) Figure 48. Asia Central Nervous System (CNS) Drug Revenue Share by Application (2021-2032) Figure 49. Asia Central Nervous System (CNS) Drug Revenue Share by Region (2021-2032) Figure 50. Japan Central Nervous System (CNS) Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. South Korea Central Nervous System (CNS) Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. India Central Nervous System (CNS) Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Australia Central Nervous System (CNS) Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Taiwan Central Nervous System (CNS) Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Southeast Asia Central Nervous System (CNS) Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. SAMEA Central Nervous System (CNS) Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 57. SAMEA Central Nervous System (CNS) Drug Revenue Share by Type (2021-2032) Figure 58. SAMEA Central Nervous System (CNS) Drug Revenue Share by Application (2021-2032) Figure 59. SAMEA Central Nervous System (CNS) Drug Revenue Share by Country (2021-2032) Figure 60. Brazil Central Nervous System (CNS) Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Argentina Central Nervous System (CNS) Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Chile Central Nervous System (CNS) Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Colombia Central Nervous System (CNS) Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Peru Central Nervous System (CNS) Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Saudi Arabia Central Nervous System (CNS) Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Israel Central Nervous System (CNS) Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. UAE Central Nervous System (CNS) Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Turkey Central Nervous System (CNS) Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Iran Central Nervous System (CNS) Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Egypt Central Nervous System (CNS) Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Prescription Drugs
  • OTC
Applications
  • Epilepsy Drugs
  • MS Therapeutics
  • Antipsychotic Drugs
  • Depression Drugs
  • Others
Companies covered
  • Tekeda
  • Teva
  • Shanghai Fosun
  • Johnson & Johnson
  • Novartis AG
  • Roche
  • Eli Lilly
  • Jiangsu Nhwa Pharmaceutical Co., Ltd.
  • Pfizer Inc
  • GSK
  • UCB
  • Otsuka Pharmaceutical Co., Ltd
  • Boehringer Ingelheim
  • Biogen Inc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Central Nervous System (CNS) Drug Market by Type
  3. 1.2.1 Global Central Nervous System (CNS) Drug Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Prescription Drugs
  5. 1.2.3 OTC
  6. 1.3 Central Nervous System (CNS) Drug Market by Application
  7. 1.3.1 Global Central Nervous System (CNS) Drug Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Epilepsy Drugs
  9. 1.3.3 MS Therapeutics
  10. 1.3.4 Antipsychotic Drugs
  11. 1.3.5 Depression Drugs
  12. 1.3.6 Others
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 Central Nervous System (CNS) Drug Market Dynamics
  1. 2.1 Central Nervous System (CNS) Drug Industry Trends
  2. 2.2 Central Nervous System (CNS) Drug Industry Drivers
  3. 2.3 Central Nervous System (CNS) Drug Industry Opportunities and Challenges
  4. 2.4 Central Nervous System (CNS) Drug Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Central Nervous System (CNS) Drug Market Perspective (2021-2032)
  2. 3.2 Global Central Nervous System (CNS) Drug Growth Trends by Region
  3. 3.2.1 Global Central Nervous System (CNS) Drug Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Central Nervous System (CNS) Drug Market Size by Region (2021-2026)
  5. 3.2.3 Global Central Nervous System (CNS) Drug Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Central Nervous System (CNS) Drug Revenue by Players
  2. 4.1.1 Global Central Nervous System (CNS) Drug Revenue by Players (2021-2026)
  3. 4.1.2 Global Central Nervous System (CNS) Drug Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Central Nervous System (CNS) Drug Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Central Nervous System (CNS) Drug Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Central Nervous System (CNS) Drug Key Players Headquarters & Area Served
  7. 4.4 Global Central Nervous System (CNS) Drug Players, Product Type & Application
  8. 4.5 Global Central Nervous System (CNS) Drug Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Central Nervous System (CNS) Drug Market CR5 and HHI
  11. 4.6.3 2025 Central Nervous System (CNS) Drug Tier 1, Tier 2, and Tier 3
5 Central Nervous System (CNS) Drug Market Size by Type
  1. 5.1 Global Central Nervous System (CNS) Drug Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Central Nervous System (CNS) Drug Revenue by Type (2021-2032)
  3. 5.3 Global Central Nervous System (CNS) Drug Revenue Market Share by Type (2021-2032)
6 Central Nervous System (CNS) Drug Market Size by Application
  1. 6.1 Global Central Nervous System (CNS) Drug Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Central Nervous System (CNS) Drug Revenue by Application (2021-2032)
  3. 6.3 Global Central Nervous System (CNS) Drug Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Tekeda
  2. 7.1.1 Tekeda Company Information
  3. 7.1.2 Tekeda Business Overview
  4. 7.1.3 Tekeda Central Nervous System (CNS) Drug Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Tekeda Central Nervous System (CNS) Drug Product Portfolio
  6. 7.1.5 Tekeda Recent Developments
  7. 7.2 Teva
  8. 7.2.1 Teva Company Information
  9. 7.2.2 Teva Business Overview
  10. 7.2.3 Teva Central Nervous System (CNS) Drug Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Teva Central Nervous System (CNS) Drug Product Portfolio
  12. 7.2.5 Teva Recent Developments
  13. 7.3 Shanghai Fosun
  14. 7.3.1 Shanghai Fosun Company Information
  15. 7.3.2 Shanghai Fosun Business Overview
  16. 7.3.3 Shanghai Fosun Central Nervous System (CNS) Drug Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Shanghai Fosun Central Nervous System (CNS) Drug Product Portfolio
  18. 7.3.5 Shanghai Fosun Recent Developments
  19. 7.4 Johnson & Johnson
  20. 7.4.1 Johnson & Johnson Company Information
  21. 7.4.2 Johnson & Johnson Business Overview
  22. 7.4.3 Johnson & Johnson Central Nervous System (CNS) Drug Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Johnson & Johnson Central Nervous System (CNS) Drug Product Portfolio
  24. 7.4.5 Johnson & Johnson Recent Developments
  25. 7.5 Novartis AG
  26. 7.5.1 Novartis AG Company Information
  27. 7.5.2 Novartis AG Business Overview
  28. 7.5.3 Novartis AG Central Nervous System (CNS) Drug Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Novartis AG Central Nervous System (CNS) Drug Product Portfolio
  30. 7.5.5 Novartis AG Recent Developments
  31. 7.6 Roche
  32. 7.6.1 Roche Company Information
  33. 7.6.2 Roche Business Overview
  34. 7.6.3 Roche Central Nervous System (CNS) Drug Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Roche Central Nervous System (CNS) Drug Product Portfolio
  36. 7.6.5 Roche Recent Developments
  37. 7.7 Eli Lilly
  38. 7.7.1 Eli Lilly Company Information
  39. 7.7.2 Eli Lilly Business Overview
  40. 7.7.3 Eli Lilly Central Nervous System (CNS) Drug Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Eli Lilly Central Nervous System (CNS) Drug Product Portfolio
  42. 7.7.5 Eli Lilly Recent Developments
  43. 7.8 Jiangsu Nhwa Pharmaceutical Co., Ltd.
  44. 7.8.1 Jiangsu Nhwa Pharmaceutical Co., Ltd. Company Information
  45. 7.8.2 Jiangsu Nhwa Pharmaceutical Co., Ltd. Business Overview
  46. 7.8.3 Jiangsu Nhwa Pharmaceutical Co., Ltd. Central Nervous System (CNS) Drug Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Jiangsu Nhwa Pharmaceutical Co., Ltd. Central Nervous System (CNS) Drug Product Portfolio
  48. 7.8.5 Jiangsu Nhwa Pharmaceutical Co., Ltd. Recent Developments
  49. 7.9 Pfizer Inc
  50. 7.9.1 Pfizer Inc Company Information
  51. 7.9.2 Pfizer Inc Business Overview
  52. 7.9.3 Pfizer Inc Central Nervous System (CNS) Drug Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Pfizer Inc Central Nervous System (CNS) Drug Product Portfolio
  54. 7.9.5 Pfizer Inc Recent Developments
  55. 7.10 GSK
  56. 7.10.1 GSK Company Information
  57. 7.10.2 GSK Business Overview
  58. 7.10.3 GSK Central Nervous System (CNS) Drug Revenue and Gross Margin (2021-2026)
  59. 7.10.4 GSK Central Nervous System (CNS) Drug Product Portfolio
  60. 7.10.5 GSK Recent Developments
  61. 7.11 UCB
  62. 7.11.1 UCB Company Information
  63. 7.11.2 UCB Business Overview
  64. 7.11.3 UCB Central Nervous System (CNS) Drug Revenue and Gross Margin (2021-2026)
  65. 7.11.4 UCB Central Nervous System (CNS) Drug Product Portfolio
  66. 7.11.5 UCB Recent Developments
  67. 7.12 Otsuka Pharmaceutical Co., Ltd
  68. 7.12.1 Otsuka Pharmaceutical Co., Ltd Company Information
  69. 7.12.2 Otsuka Pharmaceutical Co., Ltd Business Overview
  70. 7.12.3 Otsuka Pharmaceutical Co., Ltd Central Nervous System (CNS) Drug Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Otsuka Pharmaceutical Co., Ltd Central Nervous System (CNS) Drug Product Portfolio
  72. 7.12.5 Otsuka Pharmaceutical Co., Ltd Recent Developments
  73. 7.13 Boehringer Ingelheim
  74. 7.13.1 Boehringer Ingelheim Company Information
  75. 7.13.2 Boehringer Ingelheim Business Overview
  76. 7.13.3 Boehringer Ingelheim Central Nervous System (CNS) Drug Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Boehringer Ingelheim Central Nervous System (CNS) Drug Product Portfolio
  78. 7.13.5 Boehringer Ingelheim Recent Developments
  79. 7.14 Biogen Inc
  80. 7.14.1 Biogen Inc Company Information
  81. 7.14.2 Biogen Inc Business Overview
  82. 7.14.3 Biogen Inc Central Nervous System (CNS) Drug Revenue and Gross Margin (2021-2026)
  83. 7.14.4 Biogen Inc Central Nervous System (CNS) Drug Product Portfolio
  84. 7.14.5 Biogen Inc Recent Developments
8 North America
  1. 8.1 North America Central Nervous System (CNS) Drug Revenue (2021-2032)
  2. 8.2 North America Central Nervous System (CNS) Drug Revenue by Type (2021-2032)
  3. 8.2.1 North America Central Nervous System (CNS) Drug Revenue by Type (2021-2026)
  4. 8.2.2 North America Central Nervous System (CNS) Drug Revenue by Type (2027-2032)
  5. 8.3 North America Central Nervous System (CNS) Drug Revenue Share by Type (2021-2032)
  6. 8.4 North America Central Nervous System (CNS) Drug Revenue by Application (2021-2032)
  7. 8.4.1 North America Central Nervous System (CNS) Drug Revenue by Application (2021-2026)
  8. 8.4.2 North America Central Nervous System (CNS) Drug Revenue by Application (2027-2032)
  9. 8.5 North America Central Nervous System (CNS) Drug Revenue Share by Application (2021-2032)
  10. 8.6 North America Central Nervous System (CNS) Drug Revenue by Country
  11. 8.6.1 North America Central Nervous System (CNS) Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Central Nervous System (CNS) Drug Revenue by Country (2021-2026)
  13. 8.6.3 North America Central Nervous System (CNS) Drug Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe Central Nervous System (CNS) Drug Revenue (2021-2032)
  2. 9.2 Europe Central Nervous System (CNS) Drug Revenue by Type (2021-2032)
  3. 9.2.1 Europe Central Nervous System (CNS) Drug Revenue by Type (2021-2026)
  4. 9.2.2 Europe Central Nervous System (CNS) Drug Revenue by Type (2027-2032)
  5. 9.3 Europe Central Nervous System (CNS) Drug Revenue Share by Type (2021-2032)
  6. 9.4 Europe Central Nervous System (CNS) Drug Revenue by Application (2021-2032)
  7. 9.4.1 Europe Central Nervous System (CNS) Drug Revenue by Application (2021-2026)
  8. 9.4.2 Europe Central Nervous System (CNS) Drug Revenue by Application (2027-2032)
  9. 9.5 Europe Central Nervous System (CNS) Drug Revenue Share by Application (2021-2032)
  10. 9.6 Europe Central Nervous System (CNS) Drug Revenue by Country
  11. 9.6.1 Europe Central Nervous System (CNS) Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Central Nervous System (CNS) Drug Revenue by Country (2021-2026)
  13. 9.6.3 Europe Central Nervous System (CNS) Drug Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
  19. 9.6.9 Nordic Countries
10 China
  1. 10.1 China Central Nervous System (CNS) Drug Revenue (2021-2032)
  2. 10.2 China Central Nervous System (CNS) Drug Revenue by Type (2021-2032)
  3. 10.2.1 China Central Nervous System (CNS) Drug Revenue by Type (2021-2026)
  4. 10.2.2 China Central Nervous System (CNS) Drug Revenue by Type (2027-2032)
  5. 10.3 China Central Nervous System (CNS) Drug Revenue Share by Type (2021-2032)
  6. 10.4 China Central Nervous System (CNS) Drug Revenue by Application (2021-2032)
  7. 10.4.1 China Central Nervous System (CNS) Drug Revenue by Application (2021-2026)
  8. 10.4.2 China Central Nervous System (CNS) Drug Revenue by Application (2027-2032)
  9. 10.5 China Central Nervous System (CNS) Drug Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Central Nervous System (CNS) Drug Revenue (2021-2032)
  2. 11.2 Asia Central Nervous System (CNS) Drug Revenue by Type (2021-2032)
  3. 11.2.1 Asia Central Nervous System (CNS) Drug Revenue by Type (2021-2026)
  4. 11.2.2 Asia Central Nervous System (CNS) Drug Revenue by Type (2027-2032)
  5. 11.3 Asia Central Nervous System (CNS) Drug Revenue Share by Type (2021-2032)
  6. 11.4 Asia Central Nervous System (CNS) Drug Revenue by Application (2021-2032)
  7. 11.4.1 Asia Central Nervous System (CNS) Drug Revenue by Application (2021-2026)
  8. 11.4.2 Asia Central Nervous System (CNS) Drug Revenue by Application (2027-2032)
  9. 11.5 Asia Central Nervous System (CNS) Drug Revenue Share by Application (2021-2032)
  10. 11.6 Asia Central Nervous System (CNS) Drug Revenue by Country
  11. 11.6.1 Asia Central Nervous System (CNS) Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Central Nervous System (CNS) Drug Revenue by Country (2021-2026)
  13. 11.6.3 Asia Central Nervous System (CNS) Drug Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Central Nervous System (CNS) Drug Revenue (2021-2032)
  2. 12.2 SAMEA Central Nervous System (CNS) Drug Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Central Nervous System (CNS) Drug Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Central Nervous System (CNS) Drug Revenue by Type (2027-2032)
  5. 12.3 SAMEA Central Nervous System (CNS) Drug Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Central Nervous System (CNS) Drug Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Central Nervous System (CNS) Drug Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Central Nervous System (CNS) Drug Revenue by Application (2027-2032)
  9. 12.5 SAMEA Central Nervous System (CNS) Drug Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Central Nervous System (CNS) Drug Revenue by Country
  11. 12.6.1 SAMEA Central Nervous System (CNS) Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Central Nervous System (CNS) Drug Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Central Nervous System (CNS) Drug Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst